SHINGLES VACCINE MARKET ANALYSIS

Market News

Key Developments

1. Major key players in the market are focused on R&D on shingles vaccine, in order to gain competitive edge in the market. For instance, in August 2019, a team of researchers from Centre de research du Centre hospitalier de l'Université de Québec and the Université Laval, Québec, found that the Shingrix vaccine was cost-effective for adults age 60 years and above and likely more cost-effective than Zostavax.
2. Increasing approval and launch of new shingles vaccines is expected to boost the market growth. For instance, in May 2019, the National Medical Products Administration (NMPA) of China approved Shingrix, developed by GlaxoSmithKline plc for the prevention of shingles in adults aged 50 years and above.
3. Moreover, in March 2018, the European Commission and the Japanese Ministry of Health, Labor, and Welfare approved Shingrix for the prevention of shingles and post-herpetic neuralgia in adults aged 50 years and above.